PHGE · Biomx Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $21.29M | $24.66M | $16.70M | $16.24M | $22.68M | $20.93M |
| SG&A | $9.63M | $11.78M | $8.65M | $9.46M | $11.27M | $9.32M |
| Total Operating Expenses | - | - | - | $376.0K | - | - |
| D&A | $2.92M | $1.80M | $871.0K | $2.52M | $986.0K | $652.0K |
| Operating Income | ($41.47M) | ($44.52M) | ($25.35M) | ($27.22M) | ($35.46M) | ($30.26M) |
| Interest Expense | $20.0K | $850.0K | $2.40M | $2.07M | $983.0K | - |
| Income Tax | $7.0K | $13.0K | $23.0K | $65.0K | $67.0K | - |
| Net Income | ($36.20M) | ($17.73M) | ($26.17M) | ($28.32M) | ($36.23M) | ($30.09M) |
| EPS - Basic | $22.19 | $27.93 | $96.90 | $264.10 | - | - |
| EPS - Diluted | $22.19 | $63.84 | $96.90 | $264.10 | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.36M | $16.86M | $14.91M | $31.33M | $62.10M | $36.48M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $3.12M | $1.88M | $1.38M | $820.0K | $2.79M | $2.32M |
| Current Assets | $5.58M | $20.52M | $17.63M | $36.88M | $66.64M | $60.67M |
| Total Assets | $5.78M | $43.23M | $25.03M | $45.53M | $77.99M | $70.36M |
| Current Liabilities | $6.38M | $8.27M | $11.18M | $7.94M | $11.04M | $7.16M |
| Long-term Debt | - | - | $5.40M | $10.59M | $14.41M | - |
| Total Liabilities | - | - | - | - | - | - |
| Stockholders' Equity | ($1.30M) | $24.15M | $3.08M | $21.04M | $47.53M | $57.47M |
| Retained Earnings | ($216.90M) | ($180.70M) | ($162.97M) | - | - | - |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($26.39M) | ($36.98M) | ($21.29M) | ($29.09M) | ($27.57M) | ($24.45M) |
| Investing Cash Flow | $108.0K | $715.0K | $1.95M | ($2.11M) | $16.17M | ($10.86M) |
| Financing Cash Flow | $13.19M | $38.37M | $2.90M | $292.0K | $37.28M | $134.0K |
| CapEx | $2.0K | $30.0K | $50.0K | $112.0K | $3.68M | $1.01M |
| Free Cash Flow | ($26.39M) | ($37.01M) | ($21.34M) | ($29.20M) | ($31.25M) | ($25.46M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 0.73 | 2.09 | 0.82 | 1.03 | 0.86 | 0.85 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -626.0% | -41.0% | -104.6% | -62.2% | -46.4% | -42.8% |
| Return on equity | 2780.3% | -73.4% | -849.4% | -134.6% | -76.2% | -52.4% |
| Return on invested capital | - | - | -236.1% | -68.0% | -45.2% | - |
| Liquidity | ||||||
| Current ratio | 0.87 | 2.48 | 1.58 | 4.65 | 6.03 | 8.47 |
| Quick ratio | 0.87 | 2.48 | 1.58 | 4.65 | 6.03 | 8.47 |
| Cash ratio | 0.68 | 2.04 | 1.33 | 3.95 | 5.62 | 5.09 |
| Leverage | ||||||
| Debt / Equity | - | - | 1.75 | 0.50 | 0.30 | - |
| Debt / Assets | - | - | 0.22 | 0.23 | 0.18 | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -2073.3x | -52.4x | -10.5x | -13.2x | -36.1x | - |
| Equity multiplier | -4.44 | 1.79 | 8.12 | 2.16 | 1.64 | 1.22 |
| Liabilities / Assets | - | - | - | - | - | - |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | 0.1x | 0.2x | 0.5x | 0.1x | - | - |
| P / B | - | 7.5x | 886.3x | 43.9x | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 6.9% | -75.6% | 6.9% | 23.2% | -17.2% | -142.2% |
| Net income growth (YoY) | -104.2% | 32.3% | 7.6% | 21.8% | -20.4% | -136.5% |
| EPS growth (YoY) | -65.2% | -34.1% | -63.3% | - | - | - |
| EPS CAGR (3y) | -56.2% | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 28.7% | -73.5% | 26.9% | 6.6% | -22.8% | -122.5% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | - | 683.8% | -85.4% | -55.7% | -17.3% | -32.0% |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing BiomX Inc. against the 5 most active filers in the same SIC group.